irbesartan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 1481 138402-11-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • irbesartan
  • aprovel
  • irbesartan hydrochloride
  • karvea
  • ifirmasta
  • irbesartan HCl
A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
  • Molecular weight: 428.54
  • Formula: C25H28N6O
  • CLOGP: 6.04
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 1
  • TPSA: 87.13
  • ALOGS: -4.70
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.08 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 10 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.94 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 30, 1997 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 478.67 10.03 893 50104 234962 46400103
Hyponatraemia 449.19 10.03 553 50444 100779 46534286
Hyperkalaemia 158.88 10.03 234 50763 50475 46584590
Neurologic neglect syndrome 140.05 10.03 45 50952 641 46634424
Carotid artery thrombosis 137.30 10.03 45 50952 685 46634380
Lactic acidosis 129.32 10.03 172 50825 33737 46601328
Personality disorder 112.44 10.03 59 50938 3074 46631991
Adjustment disorder 105.39 10.03 44 50953 1355 46633710
Fall 92.94 10.03 646 50351 328451 46306614
Hemiplegia 91.02 10.03 69 50928 6869 46628196
Rheumatoid arthritis 81.89 10.03 85 50912 240130 46394935
Drug ineffective 79.92 10.03 426 50571 677412 45957653
Drug interaction 78.86 10.03 433 50564 202661 46432404
Drug hypersensitivity 77.92 10.03 91 50906 243734 46391331
Pain 76.14 10.03 267 50730 476681 46158384
Hypotension 75.51 10.03 473 50524 232116 46402949
Hypoglycaemia 73.68 10.03 175 50822 54174 46580891
Renal failure 72.20 10.03 280 50717 113314 46521751
Sinus bradycardia 72.09 10.03 82 50915 13700 46621365
Treatment failure 70.95 10.03 9 50988 93078 46541987
Affect lability 66.17 10.03 61 50936 7959 46627106
Hypertension 62.86 10.03 398 50599 195958 46439107
Bradycardia 60.11 10.03 184 50813 66114 46568951
Blood pressure increased 57.36 10.03 282 50715 126384 46508681
Sensory loss 55.98 10.03 52 50945 6850 46628215
Hepatocellular injury 54.84 10.03 108 50889 29414 46605651
Pemphigoid 54.31 10.03 47 50950 5644 46629421
Death 54.00 10.03 187 50810 335361 46299704
Aphasia 53.66 10.03 105 50892 28462 46606603
Hypertensive crisis 51.79 10.03 69 50928 13546 46621519
Maternal exposure during pregnancy 49.60 10.03 25 50972 102524 46532541
Muscle spasticity 48.23 10.03 61 50936 11379 46623686
Completed suicide 48.15 10.03 53 50944 145867 46489198
Motor dysfunction 48.06 10.03 49 50948 7233 46627832
Confusional state 47.41 10.03 318 50679 159574 46475491
Off label use 47.21 10.03 234 50763 379607 46255458
Hypokalaemia 46.47 10.03 205 50792 87819 46547246
Syncope 45.08 10.03 230 50767 104573 46530492
Therapeutic product effect decreased 44.91 10.03 17 50980 82584 46552481
Blood pressure systolic increased 44.89 10.03 98 50899 28689 46606376
Product dose omission issue 44.62 10.03 72 50925 168448 46466617
Rhabdomyolysis 44.41 10.03 123 50874 41786 46593279
Contraindicated product administered 44.23 10.03 16 50981 79931 46555134
Atrial fibrillation 41.56 10.03 223 50774 103367 46531698
Cholestasis 41.31 10.03 91 50906 26802 46608263
Inappropriate antidiuretic hormone secretion 41.16 10.03 63 50934 14039 46621026
Eating disorder 40.72 10.03 64 50933 14590 46620475
Atrioventricular block first degree 39.69 10.03 41 50956 6145 46628920
Shock haemorrhagic 39.60 10.03 48 50949 8576 46626489
Exposure during pregnancy 37.14 10.03 38 50959 108174 46526891
Ischaemic stroke 37.07 10.03 66 50931 16656 46618409
Vertigo 36.94 10.03 133 50864 51915 46583150
Fear of eating 36.79 10.03 14 50983 336 46634729
Hemiparesis 36.76 10.03 73 50924 19996 46615069
Coordination abnormal 36.40 10.03 52 50945 10897 46624168
Atrioventricular block complete 35.91 10.03 43 50954 7584 46627481
Dehydration 35.22 10.03 296 50701 159244 46475821
Therapeutic product effect incomplete 34.96 10.03 21 50976 78132 46556933
Cerebrovascular accident 33.01 10.03 206 50791 100833 46534232
Oedema peripheral 30.96 10.03 288 50709 159418 46475647
Synovitis 30.88 10.03 14 50983 61061 46574004
Arteriovenous fistula occlusion 30.46 10.03 12 50985 317 46634748
Blue toe syndrome 29.58 10.03 12 50985 343 46634722
Asthenia 29.39 10.03 490 50507 310585 46324480
Anuria 27.80 10.03 47 50950 11384 46623681
Prothrombin time ratio decreased 27.57 10.03 12 50985 410 46634655
Neurofibrosarcoma 27.10 10.03 9 50988 143 46634922
Tubulointerstitial nephritis 26.14 10.03 53 50944 14735 46620330
Vascular purpura 26.08 10.03 17 50980 1329 46633736
Systemic lupus erythematosus 25.83 10.03 20 50977 65160 46569905
Haematoma 25.71 10.03 85 50912 31787 46603278
Febrile neutropenia 25.43 10.03 40 50957 94587 46540478
Toxicity to various agents 25.37 10.03 132 50865 211634 46423431
Infection 25.31 10.03 69 50928 133523 46501542
Injection site erythema 24.57 10.03 27 50970 74400 46560665
Glossodynia 24.33 10.03 9 50988 44364 46590701
Dysarthria 23.43 10.03 92 50905 37406 46597659
Blood potassium increased 23.37 10.03 55 50942 16912 46618153
Angioedema 23.36 10.03 95 50902 39247 46595818
Meningorrhagia 23.32 10.03 8 50989 141 46634924
Hypergammaglobulinaemia 23.18 10.03 11 50986 461 46634604
Cutaneous vasculitis 23.03 10.03 25 50972 3966 46631099
Haemangioma congenital 22.79 10.03 11 50986 479 46634586
Blood pressure inadequately controlled 22.67 10.03 26 50971 4380 46630685
Hand deformity 22.67 10.03 5 50992 34569 46600496
Renal impairment 22.66 10.03 149 50848 74223 46560842
Injection site reaction 22.63 10.03 12 50985 47837 46587228
Psoriatic arthropathy 22.41 10.03 6 50991 36373 46598692
International normalised ratio increased 22.35 10.03 106 50891 46777 46588288
Sinus arrest 22.23 10.03 17 50980 1714 46633351
Prevertebral soft tissue swelling of cervical space 21.79 10.03 6 50991 48 46635017
Interstitial lung disease 21.52 10.03 116 50881 53833 46581232
Blood creatinine increased 21.45 10.03 150 50847 76253 46558812
Injection site pain 21.31 10.03 54 50943 107098 46527967
Hypochloraemia 21.04 10.03 17 50980 1856 46633209
Malaise 20.89 10.03 491 50506 330741 46304324
Pneumonia 20.75 10.03 288 50709 376032 46259033
Hyperlactacidaemia 20.54 10.03 18 50979 2197 46632868
Blood sodium decreased 20.33 10.03 61 50936 21665 46613400
Swelling 19.56 10.03 70 50927 124441 46510624
Orthostatic hypotension 19.21 10.03 65 50932 24593 46610472
Arthropathy 19.01 10.03 40 50957 84660 46550405
Haemodialysis 18.68 10.03 35 50962 9182 46625883
Acidosis 18.52 10.03 39 50958 11135 46623930
Histoplasmosis 18.27 10.03 15 50982 1675 46633390
Intestinal angioedema 18.08 10.03 10 50987 579 46634486
Product use issue 17.83 10.03 49 50948 94595 46540470
Abortion spontaneous 17.80 10.03 13 50984 43633 46591432
Hepatitis 17.73 10.03 76 50921 32139 46602926
Congenital musculoskeletal anomaly 17.72 10.03 9 50988 438 46634627
Alopecia 17.39 10.03 105 50892 162309 46472756
Coronary artery disease 17.33 10.03 78 50919 33674 46601391
Cardiac ventricular thrombosis 17.27 10.03 9 50988 462 46634603
Sebaceous gland infection 16.98 10.03 6 50991 116 46634949
Drug intolerance 16.85 10.03 93 50904 146956 46488109
Product use in unapproved indication 16.81 10.03 47 50950 90226 46544839
Dermatitis bullous 16.73 10.03 30 50967 7613 46627452
Joint swelling 16.43 10.03 110 50887 165963 46469102
Brucellosis 16.42 10.03 5 50992 59 46635006
Cardiac failure 16.40 10.03 146 50851 79802 46555263
Emphysematous cystitis 16.30 10.03 6 50991 131 46634934
Incision site haemorrhage 16.27 10.03 9 50988 521 46634544
Loss of consciousness 16.10 10.03 185 50812 108053 46527012
Hypochromic anaemia 16.07 10.03 13 50984 1422 46633643
Upper respiratory tract infection 16.02 10.03 28 50969 63528 46571537
Injection site pruritus 15.99 10.03 12 50985 39731 46595334
Hospitalisation 15.91 10.03 28 50969 63357 46571708
Wrong patient received product 15.88 10.03 14 50983 1723 46633342
Sepsis 15.59 10.03 86 50911 135928 46499137
Rash 15.56 10.03 285 50712 356227 46278838
Multiple sclerosis relapse 15.37 10.03 14 50983 42111 46592954
Injection site swelling 15.20 10.03 13 50984 40314 46594751
Myocardial infarction 15.10 10.03 168 50829 97360 46537705
Drug abuse 15.03 10.03 29 50968 63379 46571686
Intentional self-injury 14.85 10.03 4 50993 24162 46610903
Coronavirus test positive 14.84 10.03 6 50991 170 46634895
Product substitution issue 14.83 10.03 43 50954 14988 46620077
Pulmonary artery atresia 14.76 10.03 4 50993 30 46635035
Depression 14.74 10.03 117 50880 169987 46465078
Enterococcal sepsis 14.71 10.03 12 50985 1328 46633737
Intra-abdominal haematoma 14.62 10.03 13 50984 1618 46633447
Electrocardiogram PR prolongation 14.45 10.03 9 50988 650 46634415
Blood pressure diastolic decreased 14.35 10.03 41 50956 14170 46620895
Torsade de pointes 14.21 10.03 37 50960 12117 46622948
Injection site bruising 14.03 10.03 11 50986 35625 46599440
Renal pain 14.01 10.03 23 50974 5438 46629627
Necrotising myositis 14.01 10.03 7 50990 329 46634736
Electrolyte imbalance 13.94 10.03 46 50951 17180 46617885
Blood pressure fluctuation 13.90 10.03 68 50929 30380 46604685
Renin decreased 13.85 10.03 5 50992 103 46634962
Sinusitis 13.83 10.03 84 50913 129684 46505381
Sinus node dysfunction 13.71 10.03 20 50977 4269 46630796
Adverse drug reaction 13.66 10.03 17 50980 44345 46590720
Anaphylactic reaction 13.59 10.03 102 50895 53010 46582055
Jaundice 13.59 10.03 65 50932 28780 46606285
Retching 13.51 10.03 38 50959 13019 46622046
Malignant neoplasm progression 13.47 10.03 32 50965 64894 46570171
Platelet count decreased 13.32 10.03 60 50937 99964 46535101
Respiratory acidosis 13.29 10.03 24 50973 6124 46628941
Shock 13.16 10.03 53 50944 21792 46613273
Fatigue 13.12 10.03 538 50459 608159 46026906
Parotid gland enlargement 12.92 10.03 9 50988 785 46634280
Subacute cutaneous lupus erythematosus 12.84 10.03 13 50984 1902 46633163
Electrocardiogram QT prolonged 12.81 10.03 98 50899 51227 46583838
Dizziness 12.76 10.03 473 50524 339941 46295124
Skin sensitisation 12.73 10.03 9 50988 804 46634261
Eosinophilia 12.70 10.03 48 50949 19169 46615896
Device dislocation 12.68 10.03 4 50993 21798 46613267
Rash morbilliform 12.61 10.03 16 50981 2993 46632072
Primary hyperaldosteronism 12.58 10.03 4 50993 55 46635010
Pure white cell aplasia 12.58 10.03 4 50993 55 46635010
Disorientation 12.50 10.03 76 50921 36842 46598223
Fundoscopy abnormal 12.45 10.03 3 50994 13 46635052
Oral lichen planus 12.40 10.03 7 50990 422 46634643
Ascites 12.37 10.03 13 50984 36571 46598494
Haematoma muscle 12.34 10.03 8 50989 620 46634445
Subacute kidney injury 12.10 10.03 3 50994 15 46635050
Disease progression 12.02 10.03 55 50942 91245 46543820
Oropharyngeal swelling 11.99 10.03 9 50988 882 46634183
Transient ischaemic attack 11.91 10.03 72 50925 34831 46600234
Acute coronary syndrome 11.86 10.03 31 50966 10173 46624892
Headache 11.79 10.03 416 50581 477936 46157129
Oliguria 11.64 10.03 28 50969 8731 46626334
Hepatorenal syndrome 11.63 10.03 12 50985 1796 46633269
Blood aldosterone increased 11.60 10.03 5 50992 167 46634898
Bundle branch block left 11.39 10.03 23 50974 6376 46628689
Weight abnormal 11.36 10.03 9 50988 956 46634109
Pericarditis 11.31 10.03 6 50991 23921 46611144
Aortic valve incompetence 11.28 10.03 22 50975 5948 46629117
Tendon injury 11.27 10.03 11 50986 1541 46633524
Tricuspid valve thickening 11.25 10.03 3 50994 21 46635044
Optic nerve infarction 11.25 10.03 3 50994 21 46635044
Premature delivery 11.25 10.03 5 50992 22064 46613001
Fibrous histiocytoma 11.17 10.03 7 50990 511 46634554
Wrong technique in product usage process 11.15 10.03 27 50970 54395 46580670
Physical assault 11.04 10.03 9 50988 995 46634070
Maculopathy 10.92 10.03 11 50986 1600 46633465
Abdominal discomfort 10.88 10.03 109 50888 151056 46484009
Muscular weakness 10.68 10.03 150 50847 91694 46543371
Cerebral haemorrhage 10.64 10.03 60 50937 28311 46606754
White blood cell analysis abnormal 10.58 10.03 3 50994 27 46635038
Aortic valve thickening 10.49 10.03 3 50994 28 46635037
Drug resistance 10.44 10.03 3 50994 17365 46617700
Diabetes mellitus inadequate control 10.44 10.03 35 50962 13179 46621886
Talipes 10.27 10.03 10 50987 1397 46633668
Insulinoma 10.21 10.03 4 50993 104 46634961
Musculoskeletal stiffness 10.14 10.03 64 50933 97929 46537136
Dysphagia 10.12 10.03 129 50868 77183 46557882

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 278.79 11.08 866 36932 272976 29641704
Lactic acidosis 121.15 11.08 172 37626 31041 29883639
Death 106.57 11.08 180 37618 357103 29557577
Hyponatraemia 102.21 11.08 247 37551 66955 29847725
Hyperkalaemia 88.20 11.08 231 37567 65779 29848901
Drug abuse 70.31 11.08 10 37788 82062 29832618
Completed suicide 63.66 11.08 23 37775 99469 29815211
Hypoglycaemia 61.63 11.08 172 37626 50809 29863871
Oesophageal pain 57.42 11.08 25 37773 737 29913943
Anorectal discomfort 57.31 11.08 33 37765 1784 29912896
Hypotension 53.58 11.08 434 37364 200131 29714549
Bradycardia 50.91 11.08 190 37608 65336 29849344
Eosinophilia 50.43 11.08 96 37702 22064 29892616
Off label use 46.05 11.08 161 37637 249129 29665551
N-terminal prohormone brain natriuretic peptide abnormal 45.70 11.08 13 37785 101 29914579
Fractured coccyx 45.64 11.08 14 37784 145 29914535
Blood pressure increased 43.50 11.08 193 37605 71735 29842945
Syncope 43.45 11.08 217 37581 84686 29829994
Seronegative arthritis 40.43 11.08 20 37778 793 29913887
Blood thyroid stimulating hormone abnormal 40.28 11.08 13 37785 161 29914519
Brain natriuretic peptide abnormal 40.20 11.08 13 37785 162 29914518
Presyncope 35.84 11.08 69 37729 15987 29898693
Pulmonary arterial pressure abnormal 35.83 11.08 12 37786 168 29914512
Blood pressure systolic increased 35.05 11.08 66 37732 15044 29899636
Eczema 34.30 11.08 61 37737 13308 29901372
Febrile neutropenia 34.22 11.08 51 37747 106642 29808038
Electrocardiogram QRS complex abnormal 34.09 11.08 13 37785 270 29914410
Pneumonia 33.98 11.08 265 37533 334041 29580639
Oxygen saturation increased 33.37 11.08 12 37786 210 29914470
Drug ineffective 33.13 11.08 273 37525 340114 29574566
Treatment failure 32.74 11.08 3 37795 34676 29880004
Toxicity to various agents 32.29 11.08 115 37683 177068 29737612
Rhabdomyolysis 30.07 11.08 159 37639 63421 29851259
Disease progression 28.83 11.08 35 37763 79839 29834841
Congenital diaphragmatic anomaly 28.51 11.08 7 37791 28 29914652
Blood creatinine increased 28.37 11.08 205 37593 91170 29823510
Fall 28.26 11.08 352 37446 181520 29733160
Hypoparathyroidism 27.78 11.08 13 37785 455 29914225
Agranulocytosis 27.45 11.08 75 37723 21867 29892813
Drug interaction 27.15 11.08 377 37421 199191 29715489
Renal failure 27.08 11.08 265 37533 128701 29785979
Pemphigoid 27.02 11.08 40 37758 7488 29907192
Left ventricular dilatation 26.91 11.08 14 37784 618 29914062
Lipoma 26.91 11.08 19 37779 1464 29913216
Vomiting projectile 26.73 11.08 14 37784 627 29914053
Arrhythmia 26.42 11.08 97 37701 33072 29881608
Gastrointestinal motility disorder 25.88 11.08 22 37776 2229 29912451
Dysgeusia 25.48 11.08 79 37719 24722 29889958
Plasma cell myeloma 24.42 11.08 19 37779 53443 29861237
Antiphospholipid antibodies positive 23.28 11.08 10 37788 285 29914395
Cerebrovascular accident 22.94 11.08 182 37616 83295 29831385
Sepsis 22.85 11.08 101 37697 146294 29768386
Shock 22.73 11.08 72 37726 22787 29891893
Tongue abscess 22.71 11.08 4 37794 0 29914680
Pancreatitis acute 22.05 11.08 77 37721 25618 29889062
Hypertension 21.98 11.08 242 37556 121112 29793568
Hypovolaemia 21.73 11.08 39 37759 8566 29906114
Hyperlactacidaemia 21.23 11.08 21 37777 2585 29912095
Morganella infection 20.73 11.08 10 37788 375 29914305
Product dose omission issue 20.57 11.08 54 37744 91577 29823103
Preternatural anus 20.40 11.08 7 37791 106 29914574
Anuria 20.23 11.08 42 37756 10274 29904406
Renal haemorrhage 19.69 11.08 15 37783 1300 29913380
Ear discomfort 19.68 11.08 19 37779 2270 29912410
Neutrophil count decreased 19.50 11.08 15 37783 42439 29872241
Left atrial dilatation 19.40 11.08 17 37781 1794 29912886
Lividity 19.34 11.08 7 37791 125 29914555
Metabolic acidosis 19.31 11.08 96 37702 37365 29877315
Cerebral haematoma 19.18 11.08 26 37772 4488 29910192
Procedural failure 19.15 11.08 6 37792 67 29914613
Supraventricular extrasystoles 19.09 11.08 22 37776 3222 29911458
Lung diffusion test decreased 19.06 11.08 11 37787 597 29914083
Acute pulmonary oedema 18.90 11.08 34 37764 7481 29907199
Melaena 18.81 11.08 86 37712 32351 29882329
Hospitalisation 18.70 11.08 17 37781 44302 29870378
Dyslipidaemia 18.53 11.08 29 37769 5698 29908982
Mental status changes 18.48 11.08 12 37786 37067 29877613
Product use in unapproved indication 18.45 11.08 41 37757 73652 29841028
White blood cell count decreased 18.44 11.08 50 37748 83897 29830783
Tenoplasty 18.00 11.08 4 37794 9 29914671
Mucosal dryness 18.00 11.08 13 37785 1038 29913642
Pseudoporphyria 17.65 11.08 8 37790 260 29914420
Goitre 17.63 11.08 15 37783 1521 29913159
Carcinoma in situ of skin 17.48 11.08 6 37792 91 29914589
Malignant neoplasm progression 17.47 11.08 41 37757 72246 29842434
Oedema peripheral 17.34 11.08 207 37591 105625 29809055
Platelet count decreased 17.29 11.08 72 37726 106057 29808623
Myopathy 17.24 11.08 40 37758 10546 29904134
Carotid arteriosclerosis 17.20 11.08 12 37786 907 29913773
Echinococciasis 17.18 11.08 4 37794 12 29914668
Blood creatine phosphokinase increased 16.99 11.08 104 37694 43744 29870936
Rectal haemorrhage 16.93 11.08 88 37710 34851 29879829
Atrial thrombosis 16.91 11.08 16 37782 1865 29912815
Precancerous skin lesion 16.78 11.08 10 37788 576 29914104
Muscle strain 16.78 11.08 22 37776 3677 29911003
Cardiac ablation 16.67 11.08 10 37788 583 29914097
Conduction disorder 16.41 11.08 16 37782 1935 29912745
Toxic skin eruption 16.19 11.08 40 37758 10975 29903705
Neoplasm prostate 16.18 11.08 7 37791 203 29914477
Mycobacterium test positive 16.18 11.08 8 37790 317 29914363
Superficial spreading melanoma stage I 16.09 11.08 4 37794 17 29914663
Appetite disorder 15.76 11.08 15 37783 1761 29912919
Drug hypersensitivity 15.66 11.08 40 37758 68479 29846201
Eosinophilic pleural effusion 15.63 11.08 7 37791 221 29914459
Sneezing 15.54 11.08 23 37775 4304 29910376
Psychotic disorder 15.50 11.08 4 37794 21511 29893169
Enterochromaffin cell hyperplasia 15.40 11.08 4 37794 21 29914659
Diabetes mellitus inadequate control 15.34 11.08 43 37755 12719 29901961
Product substitution issue 15.34 11.08 37 37761 9998 29904682
Myalgia 15.32 11.08 156 37642 76511 29838169
Renal impairment 15.28 11.08 168 37630 84016 29830664
Gastrointestinal tract mucosal pigmentation 15.23 11.08 7 37791 235 29914445
Rash maculo-papular 15.19 11.08 68 37730 25350 29889330
Periorbital haematoma 15.16 11.08 8 37790 364 29914316
Vascular purpura 15.15 11.08 14 37784 1583 29913097
Tachyarrhythmia 15.13 11.08 19 37779 3042 29911638
Bundle branch block left 14.99 11.08 25 37773 5179 29909501
Thyroiditis 14.92 11.08 14 37784 1615 29913065
Bronchial haemorrhage 14.78 11.08 10 37788 719 29913961
Haematocrit increased 14.58 11.08 14 37784 1662 29913018
Lung disorder 14.39 11.08 78 37720 31391 29883289
Pruritus 14.33 11.08 219 37579 117985 29796695
Respiratory failure 14.18 11.08 72 37726 100570 29814110
Actinic keratosis 14.18 11.08 20 37778 3583 29911097
Blood osmolarity decreased 14.06 11.08 9 37789 589 29914091
Musculoskeletal discomfort 13.97 11.08 27 37771 6273 29908407
Rheumatoid arthritis 13.88 11.08 19 37779 41178 29873502
Haemochromatosis 13.65 11.08 11 37787 1034 29913646
Shock haemorrhagic 13.64 11.08 35 37763 9830 29904850
Cholestasis 13.62 11.08 65 37733 24885 29889795
Drug dependence 13.47 11.08 5 37793 21290 29893390
Extrasystoles 13.43 11.08 20 37778 3762 29910918
Hypergastrinaemia 13.35 11.08 4 37794 38 29914642
Atrial flutter 13.31 11.08 44 37754 14237 29900443
Pyroglutamic acidosis 13.29 11.08 5 37793 100 29914580
Ventricular hypokinesia 13.13 11.08 21 37777 4202 29910478
Dizziness 13.05 11.08 330 37468 194579 29720101
Hepatocellular injury 12.93 11.08 65 37733 25406 29889274
Hepatitis 12.75 11.08 59 37739 22297 29892383
Orthostatic hypotension 12.75 11.08 62 37736 23917 29890763
Asthenia 12.64 11.08 367 37431 220923 29693757
Enterocutaneous fistula 12.41 11.08 9 37789 723 29913957
Drug resistance 12.28 11.08 5 37793 20128 29894552
Blood lactic acid 12.25 11.08 7 37791 373 29914307
Therapeutic product effect incomplete 12.02 11.08 15 37783 33819 29880861
Acute coronary syndrome 11.92 11.08 41 37757 13532 29901148
Sedation 11.88 11.08 3 37795 16370 29898310
Dyspnoea exertional 11.86 11.08 81 37717 35349 29879331
Lower respiratory tract congestion 11.85 11.08 10 37788 1003 29913677
Atrial fibrillation 11.85 11.08 197 37601 107927 29806753
Vasoplegia syndrome 11.79 11.08 11 37787 1260 29913420
Inflammation 11.74 11.08 57 37741 21969 29892711
Foreign body in respiratory tract 11.69 11.08 5 37793 141 29914539
Mitral valve incompetence 11.65 11.08 40 37758 13194 29901486
Cardiac failure chronic 11.64 11.08 24 37774 5839 29908841
Tubulointerstitial nephritis 11.56 11.08 49 37749 17842 29896838
Inflammatory marker increased 11.53 11.08 17 37781 3171 29911509
Scan myocardial perfusion abnormal 11.51 11.08 4 37794 63 29914617
Concomitant disease progression 11.45 11.08 15 37783 2505 29912175
Fatigue 11.38 11.08 313 37485 320360 29594320
Cytomegalovirus infection 11.34 11.08 8 37790 23666 29891014
Pancreatic carcinoma metastatic 11.29 11.08 17 37781 3230 29911450
Haemoglobin increased 11.26 11.08 16 37782 2886 29911794
Injection site pain 11.23 11.08 13 37785 30297 29884383
Blood pressure inadequately controlled 11.22 11.08 15 37783 2555 29912125
Transient ischaemic attack 11.21 11.08 62 37736 25138 29889542
Leukopenia 11.19 11.08 35 37763 56124 29858556
Angioedema 11.15 11.08 78 37720 34306 29880374

Pharmacologic Action:

SourceCodeDescription
ATC C09CA04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
ATC C09DB05 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC C09DX07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA N0000000070 Angiotensin 2 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:61016 angiotensin receptor antagonists
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Diabetic renal disease indication 127013003
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Disorder of muscle contraindication 129565002 DOID:423
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Rhabdomyolysis contraindication 240131006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Azotemia contraindication 445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.37 acidic
pKa2 3.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST Ki 9.10 CHEMBL CHEMBL
Sodium/bile acid cotransporter Transporter INHIBITOR Ki 4.92 IUPHAR
Endothelin-1 receptor GPCR Ki 5 CHEMBL
Angiotensin II receptor GPCR IC50 8.89 CHEMBL
Type-1B angiotensin II receptor GPCR Ki 9.10 CHEMBL
Angiotensin II receptor (AT-1) type-1 GPCR IC50 8.89 CHEMBL

External reference:

IDSource
4021071 VUID
N0000148533 NUI
D00523 KEGG_DRUG
329055-23-4 SECONDARY_CAS_RN
4021071 VANDF
C4551750 UMLSCUI
CHEBI:5959 CHEBI
CHEMBL1513 ChEMBL_ID
DB01029 DRUGBANK_ID
D000077405 MESH_DESCRIPTOR_UI
3749 PUBCHEM_CID
589 IUPHAR_LIGAND_ID
7229 INN_ID
J0E2756Z7N UNII
83818 RXNORM
4917 MMSL
52343 MMSL
d04222 MMSL
006921 NDDF
108585000 SNOMEDCT_US
386877005 SNOMEDCT_US
734504000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Avapro HUMAN PRESCRIPTION DRUG LABEL 1 0024-5850 TABLET, FILM COATED 75 mg ORAL NDA 29 sections
Avapro HUMAN PRESCRIPTION DRUG LABEL 1 0024-5851 TABLET, FILM COATED 150 mg ORAL NDA 29 sections
Avapro HUMAN PRESCRIPTION DRUG LABEL 1 0024-5852 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
Avalide HUMAN PRESCRIPTION DRUG LABEL 2 0024-5855 TABLET, FILM COATED 150 mg ORAL NDA 30 sections
Avalide HUMAN PRESCRIPTION DRUG LABEL 2 0024-5856 TABLET, FILM COATED 300 mg ORAL NDA 30 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0054-0254 TABLET 150 mg ORAL ANDA 28 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0054-0255 TABLET 300 mg ORAL ANDA 28 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0093-8232 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0093-8238 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 0955-1040 TABLET, FILM COATED 75 mg ORAL NDA AUTHORIZED GENERIC 27 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 0955-1041 TABLET, FILM COATED 150 mg ORAL NDA AUTHORIZED GENERIC 27 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 0955-1042 TABLET, FILM COATED 300 mg ORAL NDA AUTHORIZED GENERIC 27 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0955-1045 TABLET, FILM COATED 150 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0955-1046 TABLET, FILM COATED 300 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 29300-212 TABLET 75 mg ORAL ANDA 23 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 29300-213 TABLET 150 mg ORAL ANDA 23 sections
Irbesartan HUMAN PRESCRIPTION DRUG LABEL 1 29300-214 TABLET 300 mg ORAL ANDA 23 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 29300-215 TABLET, FILM COATED 150 mg ORAL ANDA 26 sections
Irbesartan and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 29300-216 TABLET, FILM COATED 300 mg ORAL ANDA 26 sections
Irbesartan Human Prescription Drug Label 1 31722-160 TABLET 75 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-161 TABLET 150 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-162 TABLET 300 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-729 TABLET 75 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-730 TABLET 150 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 31722-731 TABLET 300 mg ORAL ANDA 27 sections
Irbesartan Human Prescription Drug Label 1 33342-047 TABLET 75 mg ORAL ANDA 26 sections
Irbesartan Human Prescription Drug Label 1 33342-048 TABLET 150 mg ORAL ANDA 26 sections
Irbesartan Human Prescription Drug Label 1 33342-049 TABLET 300 mg ORAL ANDA 26 sections
Irbesartan and Hydrochlorothiazide Human Prescription Drug Label 2 33342-057 TABLET, FILM COATED 150 mg ORAL ANDA 23 sections
Irbesartan and Hydrochlorothiazide Human Prescription Drug Label 2 33342-058 TABLET, FILM COATED 300 mg ORAL ANDA 23 sections